See Full Story
School Report Card: Schools assign students to play in the snow, some teachers may leave profession thanks to pandemic
Korin Miller
December 18, 2020, 10:26 AM
People enjoy an afternoon of sledding at New York s Central Park on Thursday. Some educators earned praise for asking students to play outside. (Photo by Spencer Platt/Getty Images)
Students are headed back to class amid the coronavirus pandemic, and to keep you posted on what’s unfolding throughout U.S. schools K-12 as well as colleges Yahoo Life is running a weekly wrap-up featuring news bites, interviews and updates on the ever-unfolding situation.
What Are the Differences Between the Pfizer and Moderna COVID-19 Vaccines? Here’s What We Know So Far Health.com 12/19/2020 Korin Miller
Following a new emergency use authorization (EUA) from the US Food and Drug Administration, Americans now have two vaccine options in the fight against the COVID-19 pandemic: One from pharmaceutical company Pfizer and one from biotechnology company Moderna.
Moderna s COVID-19 vaccine was officially authorized for emergency use Friday evening after an FDA panel recommended for the vaccine s approval. Pfizer s vaccine was granted its EUA on December 11. That means Moderna s vaccine will now join Pfizer s in being administered to health care workers and residents of long-term care facilities in the US the two high-risk groups recommended by the Centers for Disease Control and Prevention to receive the vaccine first.
, in-person
operations anytime soon, according to experts.
New Jersey’s plan places essential workers including school staff in a top tier of people who could receive vaccines in mid-January through February. But it will take time to administer vaccines and, even then, people could still be contagious even if they don t show symptoms.
“If we can get 150 million people vaccinated [in the U.S.], and we can then in the summer hopefully get children vaccinated before school, then maybe next fall we can begin to think about what normal looks like,” said Dr. Lawrence Kleinman, professor of pediatrics at Rutgers Robert Wood Johnson Medical School. “We’re not going to be able to approach that for a sizable length of time.”
Older patients with Hodgkin s lymphoma historically have inferior outcomes relative to their younger counterparts.
Individuals age 60 and over, who make up about 20% of the overall population, often have higher rates of advanced-stage disease at presentation. Comorbidities and decreased organ function may make them less likely to tolerate chemotherapy as well.
There s even evidence to suggest that Hodgkin s lymphoma has a different biology in this older group, with higher rates of mixed cellularity subtype and Epstein-Barr virus-associated disease. Furthermore, lower response and cure rates, as well as a greater risk of treatment-related death, have been reported with standard multi-agent regimens.
When it comes to treating older patients, geriatric assessments are a good place to start, said Andrew Evens, DO, MSc, of Rutgers Robert Wood Johnson Medical School and Rutgers Cancer Institute of New Jersey.